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INTRODUCTION
Rheumatoid arthritis (RA) is a disease charac-
terized by destructive synovial joint inflammation
leading to substantial joint damage, deformity, and
functional disability (1). The affected joints exhibit
hyperplasia of inflamed synovium infiltrated with a
range of immune cells, which induce the production
of various cytokines such as tumor necrosis factor
(TNF)-α, interleukin (IL)-1 and IL-6 (2-4). The
treatment of RA has advanced substantially in the
past two decades because of the development of ag-
gressive therapies for the early stages of the disease
and the advent of molecular targeted therapies (5,
6).
TNF-α is a key cytokine driving synovial inflam-
mation in RA (7). The introduction of anti-TNF-α
therapies has dramatically improved the treatment
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of patients with severe RA (8, 9). Three such agents
are currently available in Japan ; infliximab, etan-
ercept, and adalimumab. Infliximab is a chimeric
anti-human TNF-α monoclonal antibody, and, in
terms of its antigenicity, the use of methotrexate is
mandatory when infliximab is used (10). Etanercept
is a fully human soluble TNF receptor fusion pro-
tein, with a relatively short half-life in blood (11).
Adalimumab is a fully human monoclonal antibody
with a high specificity for TNF-α (12). On the other
hand, IL-6 is a multifunctional cytokine produced
by various cell types and binds to the membrane-
expressed IL-6 receptors (13). In patients with active
RA, high levels of IL-6 are present in the synovial
fluid and IL-6 is expressed in the synovial mem-
brane ; in addition, the levels of IL-6 correlate with
the degree of radiological joint damage (14, 15).
Tocilizumab is a humanized monoclonal antibody
against the IL-6 receptor that was developed in
Japan, and it has been shown to dramatically im-
prove the treatment of patients with RA (16).
With the advent of biological agents, the ultimate
goal for the treatment of patients with RA is remis-
sion or low disease activity in the early stage of the
disease (17). These agents induce a rapid therapeu-
tic response and play an essential role in therapies
for treating RA (18). However, not all patients re-
spond to biological agents (19), and a considerable
number of patients fail to go into remission. A re-
cent study showed that approximately 30% of pa-
tients with RA fail to respond or do not tolerate a
first anti-TNF biological agent, and approximately
50% of these patients discontinue the therapy within
2 years (20). On the other hand, Nishimoto et al.
showed that only 59.7% of patients treated with to-
cilizumab achieved the remission (21), thus sug-
gesting that a significant proportion of patients do
not respond to this type of treatment. Moreover,
some patients experienced adverse effects such as
serious infusion reactions and severe infections, and
biologic agents are substantially more expensive
than conventional disease-modified anti-rheumatic
drugs (DMARDs) (22, 23). Therefore, although it is
important to identify predictors of efficacy before
or in the early stages after the therapy, only mini-
mal data related to the factors that can identify the
patients who are most likely to respond to these
therapies have been published (24-27).
The aim of this study was to identify the clinical
factors which dictate response to biological agents.
In Japan, the clinical use of infliximab and etanercept
started in 2003 and 2005, respectively. In 2008, two
biological agents, adalimumab and tocilizumab, were
approved in Japan. Therefore, during April 1, 2009
and March 31, 2011, these four biological agents
were available for the treatment of patients with
RA. In the present study, we compared the treat-
ment responses and drug survival rates of the indi-
vidual biological agents, and examined the predic-
tors present at baseline and at 4 weeks after the
treatment that were associated with the treatment
responses.
MATERIALS AND METHODS
Patients
The present study was conducted at Tokushima
University Hospital (Univ) and its related three
medical institutions : Toyo Hospital (Toyo), Miyoshi
Municipal Mino Hospital (Mino), and Hanoura
Hospital of Orthopedics and Internal Medicine
(Hanoura). RA was diagnosed according to the 1987
American College of Rheumatology classification
criteria for RA (28). We enrolled patients with RA
who started one of four biological agents as an in-
itiating biological agent, ie., infliximab, etanercept,
adalimumab or tocilizumab.
Ninety-eight patients with RA who had started
to receive an initiating biological agent between
April 1, 2009 and March 31, 2011 were included in
the present study. All patients failed to respond sat-
isfactorily to treatment with at least one DMARD,
including methotrexate. Infliximab was administered
as intravenous drip infusions at a dose of 3 mg/kg
at weeks 0, 2, 6, and doses up to 10 mg/kg were
administered every 8 weeks thereafter (29). It was
recommended that infliximab must be administered
with methotrexate. Etanercept was administered
subcutaneously at a dose of either 25 mg/week or
50 mg/week (one 50 mg dose or two 25 mg doses)
(30). Adalimumab was administered subcutaneously
at a dose of 40 mg once biweekly (31). Tocilizumab
was administered as intravenous drip infusions every
4 weeks at a dose of 8 mg/kg (32).
Assessments
At baseline and at 4, 12, 24 and 48 weeks of fol-
low-up, we recorded various clinical data. Clinical
responses to therapy were evaluated using the dis-
ease activity score (DAS) 28-C-reactive protein
(CRP) (high disease activity,4.1 ; moderate disease
activity, 2.7 to 4.1 ; low disease activity, 2.3 to
2.7 ; remission,2.3) (33). The patient outcomes
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were assessed at week 48. The predictors of effi-
cacy at week 48 were examined at baseline. Pa-
tients who discontinued the biological agent prior
to the end of the 48-week follow-up because of lack
of efficacy were labelled as non-responders.
Statistical analysis
Data were expressed as the meanstandard de-
viation (SD). Categorical variables were expressed
as number and percentages. All tests were 2-tailed,
with differences reported as significant if p values
were less than 0.05. DAS28-CRP was analyzed us-
ing corrections for multiple comparisons according
to Steel test. Kaplan-Meier estimates of the prob-
ability for drug survival were used. When signifi-
cant interactions were detected, post hoc multiple
comparisons were made with the use of the Bon-
ferroni’s correction in which p0.008 was consid-
ered statistically significant (34).
RESULTS
Baseline characteristics
Table 1 shows the patients’ baseline characteris-
tics according to the biological agents they received.
Ninety-eight patients were initially enrolled in this
study. Etanercept was the most frequently admin-
istered biological agent (46.9%) followed by inflixi-
mab (22.4%), adalimumab (21.4%), and tocilizumab
(9.2%). The mean age was 56.2 years, and 77.6% of
the patients were female. The mean disease dura-
tion was 6.9 years. There was no significant differ-
ence in age, gender, disease duration, stage, or class
among the biological agents. The mean baseline
DAS28-CRP score showed high disease activity
(4.1) for all the biological agents, and was not sig-
nificantly different among them. In addition, there
was no significant difference in the components of
DAS28-CRP among the biological agents. Seventy
patients (71.4%) received methotrexate concurrently,
and 64 patients (65.3%) were currently taking corti-
costeroids at baseline. Methotrexate was concomi-
tantly administered to all patients treated with in-
fliximab (p=0.0042), in approximately two-thirds of
those treated with etanercept or adalimumab, and
one-third of those treated with tocilizumab. There
was no significant difference in the percentage of pa-
tients receiving corticosteroids among the biological
agents. The baseline characteristics are presented
according to the medical institutions in Table 2. Univ
had the most patients (57 patients, 58.2%). The num-
ber of patients in Toyo, Hanoura, and Mino was 21
(21.4%), 10 (10.2%), and 10 (10.2%), respectively.
Among the institutions, the patients in Toyo were
significantly younger (p=0.0267) and of higher class
(p=0.0275) than the value of all institutions. The
disease duration tended to be shorter in Univ ver-
sus the other institutions, but there was no signifi-
cance. Patients in Hanoura had significantly (p=
Table 1 Baseline characteristics according to biological agents
Biological agents infliximab etanercept adalimumab tocilizumab total
n 22 (22.4) 46 (46.9) 21 (21.4) 9 (9.2) 98 (100)
Age (yrs) 52.513.3 55.614.8 59.811.5 59.614.7 56.213.8
Female (%) 77.3 87.0 52.4 87.5 77.6
Disease duration (years) 4.86.2 6.38.5 9.310.0 9.59.5 6.98.5
Interstitial pneumonia 0 7 (15) 2 (10) 2 (22) 11 (11)
Stage 2.01.0 2.31.0 2.40.9 2.21.1 2.21.0
Class 2.00.6 2.20.7 2.10.7 2.10.6 2.10.7
DAS28-CRP 4.21.3 4.71.0 4.60.9 4.71.4 4.61.1
28 SJC 5.24.5 8.55.9 6.33.3 7.34.1 7.15.1
28 TJC 3.34.8 6.75.1 4.64.7 3.43.8 5.25.0
Patient global assessment 48.027.5 61.224.5 73.818.2 73.326.0 62.625.3
CRP (mg/dl) 2.42.3 2.32.3 3.43.3 3.63.0 2.72.6
Concurrent methotrexate use
Dose, mg/week
22 (100.0)*
7.61.1
31 (67.4)
7.31.4
14 (66.7)
6.51.6
3 (33.3)
6.52.5
70 (71.4)
7.21.4
Concurrent corticosteroid use
Dose, mg/day
14 (63.6)
5.62.3
31 (67.4)
5.32.0
11 (52.4)
5.32.5
8 (88.9)
5.11.8
64 (65.3)
5.42.3
Numbers in parentheses show percentage. Values express as meanSD. *p=0.0042 in comparison with the value of total.
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0.008) less 28 swollen joint count (SJC), but there
was no significant difference in the value of DAS28-
CRP, 28 tender joint count (TJC), patient global as-
sessment, or CRP among the institutions. There was
no significant difference in the percentage of patients
receiving methotrexate or corticosteroids among
the institutions. The numbers and percentages of
the biological agents used in the 4 institutions are
compared in Table 3. Etanercept was the most fre-
quently used biological agent in all the institutions.
In Mino and Toyo, over half of the patients were
treated with etanercept. Infliximab was the second
most frequently used biological agent in Hanoura
and Univ. Subcutaneous drugs (etanercept and
adalimumab) were mostly administered to patients
from Toyo (90.5% of patients) and Mino (90%).
Follow-up
Kaplan-Meier drug survival time was estimated
for all patients treated with biological agents (Figure
1). At week 48, 86.1%, 71.4%, 52.9% and 33.3% of pa-
tients continued the initiating etanercept, tocilizu-
mab, adalimumab, and infliximab, respectively.
There was a significant difference in drug survival
times between etanercept and infliximab at week
48 (p=0.0004). Table 4 shows the time course for
Table 3 Selection of biological agents among institutions
infliximab etanercept adalimumab tocilizumab total
Hanoura 3 (30.0) 4 (40.0) 2 (20.0) 1 (10.0) 10 (10.2)
Mino 0 6 (60.0) 3 (30.0) 1 (10.0) 10 (10.2)
Toyo 2 (9.5) 16 (76.2) 3 (14.3) 0 21 (21.4)
Univ 17 (29.8) 20 (35.1) 13 (22.8) 7 (12.3) 57 (58.2)
Total 22 (22.4) 46 (46.9) 21 (21.4) 9 (9.2) 98 (100)
Numbers in parentheses show percentage.
Table 2 Baseline characteristics according to institutions
Hospitals Hanoura Mino Toyo Univ total
n 10 10 21 57 98
Age (years) 58.914.2 63.56.9 46.615.2* 57.912.6 56.213.8
Female (%) 50.0 70.0 90.5 78.2 77.6
Disease duration (years) 6.13.5 6.02.5 5.93.1 4.63.7 6.93.5
Interstitial pneumonia 1 (10) 0 3 (14) 7 (12) 11 (11)
Stage 2.70.5 2.90.7 2.60.8 1.91.0 2.21.0
Class 2.10.3 2.30.5 2.60.6** 2.00.7 2.10.7
DAS28-CRP 4.61.0 4.31.4 4.61.0 4.71.1 4.61.0
28 SJC 3.11.5*** 6.53.1 9.87.4 7.04.1 7.15.1
28 TJC 6.04.2 3.84.8 7.15.4 4.54.9 5.25.0
Patient global assessment 65.824.6 63.520.8 58.718.7 63.629.4 62.625.3
CRP, mg/dl 3.02.3 3.33.0 1.72.2 3.02.7 2.72.6
Concurrent methotrexate use
Dose, mg/week
8 (80.0)
7.61.5
9 (90.0)
6.71.4
17 (81.0)
7.31.2
37 (64.9)
7.11.9
70 (71.4)
7.21.4
Concurrent corticosteroid use
Dose, mg/day
6 (60.0)
5.12.0
7 (70.0)
5.72.0
11 (52.4)
4.51.9
40 (70.2)
5.62.5
64 (65.3)
5.42.3
Numbers in parentheses show percentage. Values express as meanSD. *p=0.0267, **p=0.0275 and ***p=0.008 in comparison
with the value of total.
Figure 1. Kaplan-Meier drug survival time for the biological
agents which were discontinued due to a lack of efficacy. *p=
0.0004 vs. infliximab.
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the clinical data. Four patients with missing data
were excluded. Of 94 patients, 23 patients (24.5%)
discontinued treatment with the biological agents
due to adverse events, and 21 patients (22.3%) dis-
continued due to a lack of efficacy. Therefore, at
week 48, 50 patients (53.2%) continued to receive
the initiating biological agents ; of these, 30 patients
were in remission or low disease activity, and 20
patients were in moderate or high disease activity.
Table 5 shows continuation and treatment responses
according to the biological agents at week 48. The
percentage of patients who had discontinued for lack
of efficacy until week 48 were high in those treated
with infliximab (64.3%) and adalimumab (43.8%),
and were low in those treated with etanercept
(8.8%). Of the 50 patients who continued treatment
with the initiating biological agents up to week 48,
24 patients (48.0%) were in remission, 6 patients
(12.0%) had low disease activity, and 20 patients
(40.0%) had moderate or high disease activity. There
was no significant difference in the remission rates
in the patients who continued the initiating biologi-
cal agents up to week 48 among biological agents,
but a moderate or high disease activity was more
prevalent in patients treated with etanercept and
adalimumab versus those treated with infliximab and
tocilizumab.
Twenty-seven patients who discontinued the in-
itiating biological agents due to adverse events (23
patients) or missing data (4 patients) were excluded
from the efficacy analysis. Therefore, 71 patients
were included for the final efficacy analysis. The
clinical efficacy for the biological agents at 48 weeks
is shown in Figure 2. In total, 30 patients (42.2%)
were in remission or had low disease activity, and
Table 4 Time course of clinical assessments
weeks 0 4 12 24 48
discontinued
IE 0 0 1 1
AE 0 1 2 6
Remission & low disease activity 5 37 37 39 30
Moderate & high disease activities 93 60 54 35 20
discontinued
IE 0 2 7 10
AE 1 2 5 6
IE ; inefficacy, AE ; adverse event
Table 5 Continuation and treatment responses of biological agents at week 48
n discontinuedby inefficacy
continued
total
DAS28-CRP
remission low moderate or high
infliximab 14 9 (64.3) 5 (35.7) 3 (60.0) 1 (20.0) 1 (20.0)
etanercept 34 3 (8.8) 31 (91.2) 15 (48.4) 3 (9.7) 13 (41.9)
adalimumab 16 7 (43.8) 9 (56.3) 4 (44.4) 0 5 (55.6)
tocilizumab 7 2 (28.6) 5 (71.4) 2 (40.0) 2 (40.0) 1 (20.0)
Total 71 21 (29.5) 50 (70.4) 24 (48.0) 6 (12.0) 20 (40.0)
Numbers in parentheses show percentage.
Figure 2. Clinical assessments of therapy with biological agents
at week 48.
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41 patients (57.7%) had moderate or high disease
activity or discontinued due to lack of efficacy. Over
50% of the patients were in remission or had low
disease activity after receiving etanercept (52.9%)
or tocilizumab (57.1%). The percentage of patients
in remission or low disease activity was low in
those treated with infliximab (28.6%) or adalimumab
(25.0%).
Thereafter, we evaluated the efficacy of combina-
tion therapy with biological agents plus methotrexate.
Patients treated with infliximab were not included
in this analysis because all of them were combined
with methotrexate. As shown in Figure 3, there was
no significant difference in the efficacy of etanercept
and tocilizumab between monotherapy and combi-
nation therapy. Adalimumab in combination with
methotrexate tended to be superior to adalimumab
monotherapy but the difference was not statistically
significant.
Predictors of response
Achieving a low disease activity and remission is
now a realistic objective in RA management (35).
In the present study, in order to identify predictors
for a beneficial outcome, predictors of remission
and low disease activity in DAS28-CRP at week 48
were examined. Of 98 patients, 27 patients (27.6%)
who discontinued an initiating biological agent for
a reason other than lack of efficacy were excluded
from this analysis, thus leaving 71 patients in the
final analysis. The patients treated with biological
agents were divided into 2 groups according to the
efficacy data at week 48. Group 1 (named the “RL
group”) comprised patients in remission or low
disease activity and Group 2 (named the “MHD
group”) comprised patients with moderate or high
disease activity, or those who discontinued treat-
ment due to lack of efficacy. To determine the clini-
cal factors at baseline to predict the efficacy at week
48, the baseline characteristics were compared be-
tween the RL and MHD groups (Table 6). Patients
Figure 3. Comparison of DAS-CRP between patients with or
without concomitant methotrexate. The solid lines indicate
those with methotrexate, and dotted lines show those without
methotrexate.
Table 6 Comparison of baseline characteristics between RL and MHD groups
RL group MHD group P value
n 30 41
Age (years) 52.414.2 58.212.5 0.1270
Female (%) 76.7 75.6 0.9179
Disease duration, years 8.011.1 7.77.6 0.6732
Disease duration,2 years (%) 33.3 32.5 0.9414
Stage 2.31.0 2.51.0 0.4897
Class 2.10.7 2.20.6 0.3262
DAS28-CRP 4.31.1 4.81.0 0.0676
High (%) 50.0 74.4 0.0069
Moderate (%) 43.3 23.1 0.5065
28 SJC 7.96.6 7.14.0 0.6638
28 TJC 4.85.3 5.95.0 0.2255
Patient global assessment 53.825.1 67.721.7 0.0308
CRP, mg/dl 2.22.4 3.12.9 0.1365
Concurrent methotrexate use
Dose, mg/week
24 (80.0)
7.51.2
30 (73.2)
6.91.7
0.7697
0.2126
Concurrent corticosteroid use
Dose, mg/day
18 (60.0)
5.42.0
30 (63.4)
5.01.9
0.5054
0.1184
Numbers in parentheses show percentage. Values express as meanSD. RL ; remission and low disease activity, MHD ; moderate
activity, high activity, and discontinued by inefficacy, SJC ; swollen joint counts, TJC ; tender joint counts
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with a high disease activity in the DAS28-CRP
scores at baseline were significantly (p=0.0069)
more frequent in the MHD group versus the RL
group, and higher DAS28-CRP scores at baseline
were likely to be seen in patients in the MHD group
versus the RL group, although statistical significance
was not observed. The baseline patient global as-
sessments were significantly (p=0.0308) lower in
the RL group than in the MHD group. Age, gen-
der, disease duration, stage, class, 28 SJC, 28 TJC,
CRP, concurrent methotrexate use, or concurrent
corticosteroid use were not significantly different
between the two groups. To examine whether the
disease activity and response assessment to the bio-
logical agent at week 4 were related to those at
week 48, DAS28-CRP and its components at week
4 were compared between the RL and MHD groups
(Table 7). DAS28-CRP at week 4 was significantly
lower in the RL group than the MHD group. Of the
DAS28 components, 28 TJC, patient global assess-
ment, and CRP but not 28 SJC at week 4 were sig-
nificantly lower in the RL group versus the MHD
group. When the results between the baseline and
week 4 were compared in each group, DAS28-
CRP, 28 TJC, and patient global assessment were
significantly decreased in both the RL and MHD
groups. On the other hand, a significant decrease
in 28 SJC and CRP at week 4 compared with base-
line was seen in the RL group but not in the MHD
group.
Drug safety
Adverse events which resulted in discontinuation
of the biological agents were analyzed. Twenty-
three patients (23.5%) discontinued the biological
agents due to adverse events. The most common
adverse events were skin eruptions (9 cases) fol-
lowed by abnormalities in liver function (7 cases),
worsening of interstitial pneumonia (3 cases), pneu-
monia (2 cases), malignancy (one case), and hem-
orrhage from digestive tract (one case). The per-
centage of patients who discontinued due to adverse
events was 7 patients (31.9%) in infliximab, 10 pa-
tients (21.7%) in etanercept, 4 patients (19.0%) in
adalimumab, and 2 patients (22.2%) in tocilizumab.
No significant difference was seen in the rate of
adverse events among the biological agents.
DISCUSSION
In order to identify the predictors of a beneficial
outcome for the administration of biological agents
to patients with RA, the present study assessed ef-
ficacy, drug survival and safety of four biological
agents. When the disease activity was examined by
DAS28-CRP at week 48, 42.3% of patients had a low
DAS score (remission or low disease activity ; RL
group), and 33.8% of patients were considered to
be in remission. The results showed that 57.7% of
patients did not improve despite therapy, having a
high DAS score (moderate disease activity or high
disease activity, or discontinued by lack of efficacy ;
MHD group). These findings pertaining to the re-
sponse rate are in agreement with other reports
(36-38). The present study showed that the efficacy
at week 48 was not different among the biological
agents in the patients who continued the biological
agents up to week 48 ; however, a difference was
observed when the patients who discontinued the
biological agents due to lack of efficacy were in-
cluded in the analysis. The proportion of patients
who discontinued the biological agents due to a
lack of efficacy was higher in the patients treated
with infliximab or adalimumab and was lower in
those treated with etanercept. Etanercept achieved
Table 7 Disease activity at weeks 0 and 4 in RL and MHD groups
RL group
n=30
MHD group
n=41 p*
baseline week 4 p baseline week 4 p
DAS28-CRP 4.31.1 2.71.1 0.0001 4.81.0 3.91.1 0.0003 0.0002
28 SJC 7.96.6 5.05.5 0.0079 7.14.0 5.64.0 0.1239 0.1645
28 TJC 4.85.3 1.83.0 0.0111 5.95.0 3.63.8 0.0208 0.0133
Patient global assessment 53.825.1 27.623.1 0.0001 67.721.7 47.725.9 0.0013 0.0033
CRP, mg/dl 2.22.4 0.40.7 0.0004 3.12.9 2.12.9 0.1243 0.0031
Values express as meanSD. *p value between RL group and MHD group at week 4. RL ; remission and low disease activity,
MHD ; moderate activity, high activity, and discontinued by inefficacy, SJC ; swollen joint counts, TJC ; tender joint counts, CRP ; c-
reactive protein
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a higher 48-week remission rate than the other
biological agents. The proportion of patients in the
RL group was higher in the patients treated with
etanercept or tocilizumab versus those treated with
infliximab or adalimumab. The drug survival rate
was also shown to be higher for etanercept and
tocilizumab. These results in which etanercept and
tocilizumab showed superior efficacy are in agree-
ment with those in other reports (39-41). The drug
survival and the proportion of patients achieving
DAS28 remission were significantly better for etan-
ercept in comparison to infliximab or adalimumab
(42), and etanercept had a longer drug survival rate
than infliximab or adalimumab (37). On the other
hand, a high proportion (59.7%) of patients treated
with tocilizumab was shown to achieve DAS-defined
remission (21). Patients who received tocilizumab
showed similar drug survival rates when compared
with TNF inhibitor, but DAS remission rates at 6
months were higher for tocilizumab (66.7%) versus
TNF inhibitors, including infliximab, etanercept and
adalimumab (25.8%) (43).
Cytokine-blocking agents have been shown to
result in a significant decrease in acute phase reac-
tions such as CRP. In particular, tocilizumab led to
a normal CRP level in almost all patients (44), thus
indicating that CRP in the DAS score might lead to
an overestimation in the efficacy of tocilizumab.
Therefore, when the efficacy of biological agents
including tocilizumab is assessed, more stringent
remission criteria such as Clinical Disease Activity
Index in which CRP is excluded should be used,
in light of the absence of acute phase reactions (17).
A problem associated with the use of infliximab is
that its efficacy often decreases during prolonged
treatment (45, 46), thus supporting the present data
that infliximab had the lowest drug survival rate. In
the case of infiximab treatment, depending on the
primary or secondary failure, the dosage of inflixi-
mab could be increased to a maximum of 10 mg/
kg administered at 4 - to 8 -week intervals (29).
Therefore, in instances when infliximab dosage is
insufficient, higher dosages will improve the treat-
ment response. We cannot rule out that the dos-
age of infliximab was insufficient in some patients
throughout the survey.
Although therapies with biological agents repre-
sent an important advancement in the treatment of
patients with RA, there is a proportion of patients
who do not improve despite therapy and these drugs
have some serious toxicities and are expensive (47).
Therefore, it would be ideal to predict the patients
who will respond to these agents. In this study, we
aimed to identify specific clinical factors that pre-
dict the response to biological agents in patients
with RA. In this observational study of response to
biological agents, certain factors emerged as inde-
pendent predictors of response. Patients were di-
vided into 2 groups, RL and MHD groups, accord-
ing to the DAS score at week 48. The RL group
comprised patients in remission or low disease ac-
tivity, and the MHD group comprised those with a
moderate or high disease activity, or those who dis-
continued due to lack of efficacy. With respect to
the DAS28 response, the patients with a high dis-
ease activity in baseline DAS28-CRP were signifi-
cantly less likely to be in the RL group. Baseline
DAS28-CRP itself was likely to be lower in the RL
group than in the MHD group. These results sug-
gest that the low level of baseline disease activity
is a strong predictor of the efficacy at week 48. Of
the DAS28-CRP components, only high patient
global assessments were significantly less likely to
achieve remission or low disease activity for thera-
pies with the biological agents. Previous reports
showed that patients with moderate disease activity
at baseline were significantly likely to be in remis-
sion at 6 months after treatment with etanercept
compared with those with high disease activity (48),
and that the disease activity at baseline was inversely
associated with the response to anti-TNF inhibitors
(infliximab, etanercept, and adalimumab) (49) . The
data presented here indicate that low DAS28-CRP
and patient global assessments at baseline are use-
ful predictors of the efficacy of four biological agents
(infliximab, etanercept, adalimumab, and tocilizu-
mab) in the treatment of RA.
There was no significant difference in other base-
line characteristics, including age, gender, disease
duration, stage, class, and the concurrent use of
methotrexate or corticosteroid between the RL and
MHD groups. Whether the disease duration and
concurrent use of methotrexate could predict the
treatment response still remains controversial. Some
clinical trial reports have demonstrated that disease
duration may influence the treatment response to
biological agents in patients with RA (18, 50, 51).
At 6 months after first-line tocilizumab treatment,
the remission rate according to DAS28 was 49.6%
in recent-onset patients compared with 21% in pa-
tients with the disease for10 years (21), and dis-
ease duration before starting anti-TNF-α agents in
patients with RA predicted drug retention (48).
This result might be expected, as an increasing
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disease duration would be associated with a more
irreversible disease. On the other hand, other re-
ports showed that the disease duration did not pre-
dict the response to infliximab and etanercept (36)
and to infliximab, etanercept and adalimumab (52),
which is a finding that is consistent with the present
study. Previous reports showed that a low health
assessment questionnaire (HAQ) at baseline pre-
dicted a good clinical outcome (36, 49, 53), but we
did not examine HAQ in this study. To determine
whether the degree of disability rather than dis-
ease duration in itself may be responsible for DAS
response, the role of functional capacity such as
HAQ as the predictor for the treatment response
may need to be examined. The concurrent use of
methotrexate was shown to be a good predictor of
the response for etanercept (48, 54), for infliximab
and etanercept (36), and for infliximab, etanercept
and adalimumab (36, 42, 49). On the other hand, a
recent report showed that concomitant methotrexate
use was not a predictor of treatment response to
TNF inhibitors (37). Although the difference was
suggested to be due to the response criteria chosen,
such as the European League against Rheumatism
(EULAR) responses using DAS28 and ACR re-
sponse criteria (37), the reason for the controver-
sial results is unknown. Further studies are needed
to clarify the validity of predictors for the response
of biological agents.
The RL group showed a significantly lower DAS
28-CRP at week 4 versus the MHD group. Of the
DAS components, 28 TJC, patient global assess-
ment, and CRP at week 4 was significantly lower in
the RL group than in the MHD group. To deter-
mine the predictors of a 48-week response at week
4, the change in DAS28 response from baseline to
week 4 was compared between the RL and MHD
groups. DAS28-CRP, 28 TJC, and patient global as-
sessment were all found to significantly decrease
at week 4 in both groups when compared with those
at baseline. However, 28 SJC and CRP significantly
decreased in the RL group, but not in the MHD
group. These data indicate that decreases in 28
SJC and CRP at week 4 were therefore useful pre-
dictors for sustaining the efficacy up to week 48.
The decision to select an initiating biologic agent
is highly dependent on various factors such as dis-
ease severity, comorbidities, patient choice and com-
pliance, and overall cost (55). There is no reason
to prefer one particular biological agent due to effi-
cacy because there is strong evidence that all the
evaluated biological agents were able to reduce
synovitis and erosive damage, which thus resulted
in an improved disability and quality of life (17, 56).
The present study showed that the disease severity
was not responsible for the selection of an initiating
biological agent because there was no significant
difference in the baseline DAS28-CRP score among
the biologic agents. The preference due to physi-
cians may be another important factor. In the pre-
sent study, etanercept was the most used biological
agent (46.9%) followed by infliximab, adalimumab,
and tocilizumab. Since infliximab and etanercept
were approved early in Japan in 2003 and 2005,
respectively, they have since been widely used to
treat RA patients, thus resulting in the physicians’
familiarity with these products. On the other hand,
adalimumab and tocilizumab were approved in 2008,
just before the start of this study. In this 2-year
study, the number of patients treated with adalimu-
mab or tocilizumab was low in the first year, but in-
creased in the second year (data not shown), thus
suggesting that the physician’s familiarity with
adalimumab and tocilizumab had been increased by
usage. Both the route and frequency of administra-
tion may influence the preference. To assess the
variation in the usage of biological agents, this
study compared an initiating biological agent among
the medical institutions, and showed that there
were certain differences among the institutions in
the selection of biological agents. Since etanercept
and adalimumab were administered subcutaneously,
efforts to effectively teach the method of self-injec-
tion to patients were therefore needed. These ef-
forts were not needed in patients treated with in-
fliximab or tocilizumab which were administered
as intravenous drip infusions, but careful observa-
tion by the medical staffs was needed during the
infusions. These differences may influence the se-
lection of biological agents in medical institutions
because the number of medical staffs working in
patient care is different among them. Chilton F et
al. examined the treatment preferences and choices
which RA patients would make when faced with
anti-TNF-α therapy options, and showed that 41%
of the RA patients wanted their rheumatologist to
make treatment decisions for anti-TNF-α treat-
ments, 33% wanted to make the decision them-
selves, and 7% preferred a joint decision (57). The
present study showed that subcutaneous drugs were
preferred at some institutions rather than intrave-
nous drugs, and they were likely to be continued up
to week 48 for patients even with a moderate or high
disease activity. This result suggests that medical
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institutions should improve both their equipment
and staff training to be able to select the biological
agent that is most suitable for each patient.
In conclusion, we compared the efficacy of bio-
logical agents in RA patients, and found that etan-
ercept achieved the highest treatment responses
and remission rate, while it also had the longest
drug survival rates. Furthermore, we showed that
patients with a high disease activity at the baseline
DAS28-CRP were predictors of the treatment re-
sponse to biological agents, and of DAS28-CRP
components, high patient global assessments were
significantly less likely to achieve good response.
Moreover, decreases in 28 SJC and CRP at week 4
were found to be useful predictors for sustaining
the efficacy up to week 48.
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